Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Cohort Study Reveals Patients Treated with Rituximab Have Poorer COVID-19 Outcomes

Lara C. Pullen, PhD  |  June 7, 2021

According to a recent cohort study, patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab therapy experience more severe COVID-19. Researchers also found an association between rituximab use and prolonged hospital stays.

Filed under:Conditions Tagged with:COVID-19Outcomesrituximab

COVID-19 Outcomes in Patients with Rheumatic Disease

Arthritis & Rheumatology  |  June 1, 2021

In a study of patients with systemic autoimmune rheumatic diseases (ARDs) and matched comparators with COVID-19 but without systemic ARDs, D’Silva et al. found COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission and more than matched comparators.

Filed under:ConditionsResearch Rheum Tagged with:Arthritis & RheumatologyAutoimmune diseaseCOVID-19OutcomesResearch

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2021

Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptinjection pensyringeYLB113-002

Virtual Hill Day Drives 100+ Congressional Conversations on Step Therapy, Workforce Shortages

From the College  |  May 25, 2021

On May 20, ACR representatives held more than 100 video meetings with Congressional leaders about the need to reform step therapy and alleviate pediatric workforce shortages. You can still add your voice by asking your members of Congress to support the Safe Step Act and fund the Pediatric Subspecialty Loan Repayment Program.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:ACR advocacyGovernment Affairs Committee (GAC)pediatric loan repaymentstep therapyVirtual Hill Day

Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease

Jason Liebowitz, MD, FACR  |  May 24, 2021

Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.

Filed under:ConditionsMeeting Reports Tagged with:ACR State-of-the-Art Clinical SymposiumIBDinflammatory bowel disease (IBD)

The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab

Michele B. Kaufman, PharmD, BCGP  |  May 24, 2021

As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsdenosumabEB1001monoclonal antibody

Pegloticase Safe & Effective for Patients with Gout on Dialysis

Michele B. Kaufman, PharmD, BCGP  |  May 19, 2021

Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:dialysisGoutpegloticase

IgG4-Related Disease: The Latest On Its Presentation, Diagnosis & Management

Jason Liebowitz, MD, FACR  |  May 13, 2021

In 1888, Dr. Jan Mikulicz-Radecki reported a case of chronic, bilateral, painless enlargement of the salivary and lacrimal glands that appeared to be idiopathic.1 In subsequent years, other patients with these findings were reported, and the term Mikulicz syndrome was used to describe these cases. Although Mikulicz syndrome is now known to be associated with…

Filed under:ConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:2021 State of the Art Clinical SymposiumIgG4 related disease

Rheum After 5: Dr. Garg Applies Coffee as an Art Medium

Carol Patton  |  May 13, 2021

Some artists paint with oils or watercolors, others with acrylics. Shivani Garg, MD, MS, prefers Nescafé or Maxwell House coffee. A faculty member in the Division of Rheumatology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, Dr. Garg learned this technique—painting with instant coffee mixed…

Filed under:ProfilesRheum After 5 Tagged with:Dr. Shivani Garg

Rheumatology Research Foundation Funds 5 COVID-19 Studies for $1.65 Million

Kimberly Retzlaff  |  May 13, 2021

In spring 2020, as it became obvious that COVID-19 wasn’t going anywhere anytime soon, the leaders of the Rheumatology Research Foundation implemented an expedited process to distribute research funding beyond its typical awards program. This resulted in the Foundation awarding $1.65 million to fund five research studies that will look at the relationships between rheumatic…

Filed under:From the CollegeResearch Rheum Tagged with:COVID-19GrantsRheumatology Research Foundation

  • « Previous Page
  • 1
  • …
  • 72
  • 73
  • 74
  • 75
  • 76
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences